On April 26, 2018, the China Drug Administration (CDA) released a draft guideline of implementing rules on pharmaceutical data exclusivity for public comments. The draft guideline expands the scope of data protection from...more
5/29/2018
/ Applications ,
China ,
Clinical Trials ,
Data Protection ,
Draft Guidance ,
Drug Pricing ,
Drug Safety ,
Food and Drug Administration (FDA) ,
Marketing Exclusivity Periods ,
Orphan Drugs ,
Pharmaceutical Industry ,
Public Comment ,
Public Information